Marketing of unproven stem cell-based interventions: A call to action

Douglas Sipp; Timothy Caulfield; Jane Kaye; Jan Barfoot; Clare Blackburn; Sarah Chan; Michele De Luca; Alastair Kent; Christopher McCabe; Megan Munsie; Margaret Sleeboom-Faulkner; Jeremy Sugarman; Esther Van Zimmeren; Amy Zarzeczny; John E.J. Rasko

doi:10.1126/scitranslmed.aag0426

Marketing of unproven stem cell-based interventions: A call to action

Douglas Sipp
, Timothy Caulfield
, Jane Kaye
, Jan Barfoot
, Clare Blackburn
, Sarah Chan
, Michele De Luca
, Alastair Kent
, Christopher McCabe
, Megan Munsie
, Margaret Sleeboom-Faulkner
, Jeremy Sugarman
, Esther Van Zimmeren
, Amy Zarzeczny
, John E.J. Rasko

Academic Centers

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Abstract

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

Original language	English (US)
Article number	aag0426
Journal	Science translational medicine
Volume	9
Issue number	397
DOIs	https://doi.org/10.1126/scitranslmed.aag0426
State	Published - Jul 5 2017

ASJC Scopus subject areas

General Medicine

Access to Document

10.1126/scitranslmed.aag0426

Cite this

Sipp, D., Caulfield, T., Kaye, J., Barfoot, J., Blackburn, C., Chan, S., De Luca, M., Kent, A., McCabe, C., Munsie, M., Sleeboom-Faulkner, M., Sugarman, J., Van Zimmeren, E., Zarzeczny, A., & Rasko, J. E. J. (2017). Marketing of unproven stem cell-based interventions: A call to action. Science translational medicine, 9(397), Article aag0426. https://doi.org/10.1126/scitranslmed.aag0426

@article{f914db0f31e04365b38a275c99912ded,

title = "Marketing of unproven stem cell-based interventions: A call to action",

abstract = "Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.",

author = "Douglas Sipp and Timothy Caulfield and Jane Kaye and Jan Barfoot and Clare Blackburn and Sarah Chan and \{De Luca\}, Michele and Alastair Kent and Christopher McCabe and Megan Munsie and Margaret Sleeboom-Faulkner and Jeremy Sugarman and \{Van Zimmeren\}, Esther and Amy Zarzeczny and Rasko, \{John E.J.\}",

year = "2017",

month = jul,

day = "5",

doi = "10.1126/scitranslmed.aag0426",

language = "English (US)",

volume = "9",

journal = "Science translational medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "397",

}

TY - JOUR

T1 - Marketing of unproven stem cell-based interventions

T2 - A call to action

AU - Sipp, Douglas

AU - Caulfield, Timothy

AU - Kaye, Jane

AU - Barfoot, Jan

AU - Blackburn, Clare

AU - Chan, Sarah

AU - De Luca, Michele

AU - Kent, Alastair

AU - McCabe, Christopher

AU - Munsie, Megan

AU - Sleeboom-Faulkner, Margaret

AU - Sugarman, Jeremy

AU - Van Zimmeren, Esther

AU - Zarzeczny, Amy

AU - Rasko, John E.J.

PY - 2017/7/5

Y1 - 2017/7/5

N2 - Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

AB - Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. Here, we suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments.

UR - https://www.scopus.com/pages/publications/85021874173

UR - https://www.scopus.com/pages/publications/85021874173#tab=citedBy

U2 - 10.1126/scitranslmed.aag0426

DO - 10.1126/scitranslmed.aag0426

M3 - Review article

C2 - 28679655

AN - SCOPUS:85021874173

SN - 1946-6234

VL - 9

JO - Science translational medicine

JF - Science translational medicine

IS - 397

M1 - aag0426

ER -

Marketing of unproven stem cell-based interventions: A call to action

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this